Clinical utility of daptomycin in infective endocarditis caused by Gram-positive cocci

International Journal of Antimicrobial Agents

Volumn 38, Issue 5, 2011, Pages 365-370

  Cervera, Carlos ^a   Castañeda, Ximena ^a   Pericas, Juan M ^a   Del Río, Ana ^a   De La Maria, Cristina García ^a   Mestres, Carlos ^a   Falces, Carlos ^a   Marco, Francesc ^a   Moreno, Asuncion ^a   Miró, Jose M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Coagulase negative staphylococci; Daptomycin; Enterococci; Infective endocarditis; Outpatient parenteral antimicrobial therapy; Staphylococcus aureus; Viridans group streptococci

Indexed keywords

AMPICILLIN; CEFTRIAXONE; CLOXACILLIN; COAGULASE; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FOSFOMYCIN; GENTAMICIN; GLYCOPEPTIDE; LINEZOLID; METICILLIN; NAFCILLIN; OXACILLIN; PENICILLIN G; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL ENDOCARDITIS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE COCCI; GRAM POSITIVE INFECTION; HUMAN; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; STREPTOCOCCUS VIRIDANS INFECTION; TREATMENT RESPONSE;

EID: 80053345054     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.11.038     Document Type: Short Survey

References (43)

1. D.R. Murdoch, G.R. Corey, B. Hoen, J.M. Miró, V.G. Fowler Jr., and A.S. Bayer Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study Arch Intern Med 169 2009 463 473
2. V.H. Chu, C.W. Woods, J.M. Miro, B. Hoen, C.H. Cabell, and P.A. Pappas Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis Clin Infect Dis 46 2008 232 242 (Pubitemid 351269162)
3. V.G. Fowler Jr., H.W. Boucher, G.R. Corey, E. Abrutyn, A.W. Karchmer, and M.E. Rupp Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus N Engl J Med 355 2006 653 665
4. Z. Kanafani, H. Boucher, V. Fowler, C. Cabell, B. Hoen, and J.M. Miró Daptomycin compared to standard therapy for the treatment of native valve endocarditis Enferm Infecc Microbiol Clin 28 2010 498 503
5. D.P. Levine, and K.C. Lamp Daptomycin in the treatment of patients with infective endocarditis: experience from a registry Am J Med 120 10 Suppl. 1 2007 S28 S33 (Pubitemid 47470058)
6. L.M. Baddour, W.R. Wilson, A.S. Bayer, V.G. Fowler Jr., A.F. Bolger, and M.E. Levison Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America Circulation 111 2005 e394 e434
7. G. Habib, B. Hoen, P. Tornos, F. Thuny, B. Prendergast, and I. Vilacosta Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC) Eur Heart J 30 2009 2369 2413
8. F.Y. Chang, J.E. Peacock Jr., D.M. Musher, P. Triplett, B.B. MacDonald, and J.M. Mylotte Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study Medicine (Baltimore) 82 2003 333 339 (Pubitemid 37229468)
9. T.P. Lodise Jr., P.S. McKinnon, D.P. Levine, and M.J. Rybak Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus Antimicrob Agents Chemother 51 2007 3731 3733 (Pubitemid 47519366)
10. G. Wang, J.F. Hindler, K.W. Ward, and D.A. Bruckner Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period J Clin Microbiol 44 2006 3883 3886 (Pubitemid 44737223)
11. L.K. Hidayat, D.I. Hsu, R. Quist, K.A. Shriner, and A. Wong-Beringer High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity Arch Intern Med 166 2006 2138 2144 (Pubitemid 44631403)
12. P.A. Moise-Broder, G. Sakoulas, G.M. Eliopoulos, J.J. Schentag, A. Forrest, and R.C. Moellering Jr. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy Clin Infect Dis 38 2004 1700 1705 (Pubitemid 38781661)
13. G. Sakoulas, P.A. Moise-Broder, J. Schentag, A. Forrest, R.C. Moellering Jr., and G.M. Eliopoulos Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia J Clin Microbiol 42 2004 2398 2402 (Pubitemid 38747480)
14. A. Soriano, F. Marco, J.A. Martínez, E. Pisos, M. Almela, and V.P. Dimova Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 46 2008 193 200 (Pubitemid 351269157)
15. D.P. Levine, B.S. Fromm, and B.R. Reddy Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis Ann Intern Med 115 1991 674 680
16. V.G. Fowler Jr., J.M. Miro, B. Hoen, C.H. Cabell, E. Abrutyn, and E. Rubinstein Staphylococcus aureus endocarditis: a consequence of medical progress JAMA 293 2005 3012 3021 [Erratum in: JAMA 2005;294:900] (Pubitemid 40965071)
17. I.G. Bae, J.J. Federspiel, J.M. Miró, C.W. Woods, L. Park, and M.J. Rybak Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance J Infect Dis 200 2009 1355 1366
18. F. Scaglione, and L. Paraboni Influence of pharmacokinetics/ pharmacodynamics of antibacterials in their dosing regimen selection Expert Rev Anti Infect Ther 4 2006 479 490 (Pubitemid 43905469)
19. A.C. Cremieux, B. Maziere, J.M. Vallois, M. Ottaviani, A. Azancot, and H. Raffoul Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography J Infect Dis 159 1989 938 944 (Pubitemid 19113081)
20. F. Marco, C.G. de la Mria, Y. Armero, E. Amat, D. Soy, and A. Moreno Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus Antimicrob Agents Chemother 52 2008 2538 2543 (Pubitemid 351915686)
21. T.P. Lodise, B. Lomaestro, J. Graves, and G.L. Drusano Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity Antimicrob Agents Chemother 52 2008 1330 1336 (Pubitemid 351521995)
22. M. Sharma, K. Riederer, P. Chase, and R. Khatib High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia Eur J Clin Microbiol Infect Dis 27 2008 433 437 (Pubitemid 351713065)
23. J.M. Miró, C. García-de-la-Mria, Y. Armero, D. Soy, A. Moreno, and A. del Río Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 53 2009 4172 4177
24. J. Miro, J. Entenza, A. Del Rio, C. Garcia de la Maria, M. Giddey, and Y. Armero Daptomycin (DAP) plus fosfomycin (FOM) is synergistic against methicillin-susceptible (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) strains: from bench to bedside 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 12-15 September 2009, San Francisco, CA 2009 ASM Press Washington, DC
25. J.M. Miró, J. Entenza, A. del Río, C. García de la María, M. Giddey, and Y. Armero In vitro activity of daptomycin (DAP) plus oxacillin (OXA) against methicillin-susceptible (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) strains 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 12-15 September 2010, Boston, MA 2010 ASM Press Washington, DC
26. M.E. Steed, C. Vidaillac, and M.J. Rybak Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations Antimicrob Agents Chemother 54 2010 5187 5192
27. M. Benvenuto, D.P. Benziger, S. Yankelev, and G. Vigliani Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers Antimicrob Agents Chemother 50 2006 3245 3249 (Pubitemid 44527494)
28. H.F. Chambers, L. Basuino, B.A. Diep, J. Steenbergen, S. Zhang, and P. Tattevin Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis Antimicrob Agents Chemother 53 2009 1463 1467
29. R. Kullar, S. Davis, C. Crank, J. Segreti, S. Cosgrove, and J. Zhao High-dose daptomycin for infective endocarditis 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 10-13 April 2010, Vienna, Austria 2010 European Society of Clinical Microbiology and Infectious Diseases Basel, Switzerland
30. P. Dohmen, A. Guleri, N. Petrosillo, R. Utili, V. González Sanz, and R.A. Seaton Daptomycin for the treatment of infective endocarditis: results from European Cubicin Outcomes Registry and Experience (EU-CORE) 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 10-13 April 2010, Vienna, Austria 2010 European Society of Clinical Microbiology and Infectious Diseases Basel, Switzerland
31. A. De Alarcon, M. Valerio, D. Sousa, A. Arnaiz, M. Montejo-Baranda, and M. Moreno Use of daptomycin in left-sided endocarditis. Experience in a multicenter cohort in Spain XIV Congress of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) 19-22 May, Barcelona, Spain 2010
32. F. Marco, Y. Armero, C. García de la María, A. Moreno, C. Cervera, and S. Ninot Trend in glycopeptide and daptomycin susceptibility in coagulase-negative staphylococci (CoNS) isolated from infective endocarditis (IE) over time (1992-2007) 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th Infectious Diseases Society of America (IDSA) annual meeting 25-28 October 2008, Washington, DC 2008 ASM Press Washington, DC
33. C. Cervera, X. Castañeda, C. García de la María, A. del Río, F. Marco, and Y. Armero Influence of methicillin susceptibility and vancomycin minimum inhibitory concentration on the outcome of coagulase-negative staphylococcus endocarditis 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 12-15 September 2010, Boston, MA 2010 ASM Press Washington, DC
34. C. García-de-la-Mria, F. Marco, Y. Armero, D. Soy, A. Moreno, and A. del Río Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis Antimicrob Agents Chemother 54 2010 2781 2786
35. B. Knoll, I.M. Tleyjeh, J.M. Steckelberg, W.R. Wilson, and L.M. Baddour Infective endocarditis due to penicillin-resistant viridans group streptococci Clin Infect Dis 44 2007 1585 1592 (Pubitemid 46871505)
36. T. Li, L. Mortin, S. Zhang, A. Vanpraagh, L. Chen, and X. Zhang Bactericidal efficacy of daptomycin (DAP) in rat fibrin clot model versus clinical viridans group Streptococcus (VGS) strains 43rd annual meeting of the Infectious Diseases Society of America (IDSA) 6-9 October 2005, San Francisco, CA 2005 IDSA Arlington, VA
37. J. Gavald, O. Len, J.M. Miró, P. Muñoz, M. Montejo, and A. Alarcón Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone Ann Intern Med 146 2007 574 579 (Pubitemid 351650538)
38. J.L. Mainardi, L. Gutmann, J.F. Acar, and F.W. Goldstein Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis Antimicrob Agents Chemother 39 1995 1984 1987
39. M.M. Andrews, and C.F. von Reyn Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis Clin Infect Dis 33 2001 203 209 (Pubitemid 32643335)
40. C.A. Monteiro, and C.G. Cobbs Outpatient management of infective endocarditis Curr Infect Dis Rep 3 2001 319 327
41. Cervera C, del Rio A, Garcia L, Sala M, Oliveira A, Almela M, et al. Outpatient antimicrobial therapy (OPAT) for infective endocarditis (IE). A 10-years prospective observational study [Abstract # 425]. In: 9th international symposium of modern concepts in endocarditis and cardiovascular infections. Heidelberg, Germany; 2007. Clinical Research in Cardiology. 2007; 96:425.
42. M.R. Amodeo, T. Clulow, J. Lainchbury, D.R. Murdoch, K. Gallagher, and A. Dyer Outpatient intravenous treatment for infective endocarditis: safety, effectiveness and one-year outcomes J Infect 59 2009 387 393
43. W.J. Martone, K.C. Lindfield, and D.E. Katz Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry Int J Clin Pract 62 2008 1183 1187 (Pubitemid 351977621)